SecBot SecBot
8-K ·Filed Aug 4, 2026

IDYA

IDEAYA Biosciences, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago SEC0001193125-26-331381
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The Q2 print itself is a non-event for a pre-revenue biotech, the wider loss was expected given rising trial costs. The key catalysts are the darovasertib NDA filing (H2 2026) and data readouts at ESMO (October 2026). Monitor for FDA acceptance of the NDA and any updates on the IDE849 registrational trial design. The stock may trade on pipeline milestones rather than quarterly financials.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$36.11
T+0 close · Aug 4, 2026 · via day close
Latest settled
−7.23%
T+60 · $33.50
Vs SPY
−7.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 4 $36.11entry
  2. T+1 · 3mo ago −0.19%α +0.01% · $36.04
  3. T+5 · 3mo ago +2.02%α +2.12% · $36.84
  4. T+20 · 3mo ago +10.63%α +11.87% · $39.95
  5. T+60 · 20d ago −7.23%α −7.60% · $33.50
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

IDEAYA Biosciences reported Q2 2026 results with a net loss of $112.5M ($-1.22/share), a wider loss than the prior quarter's $98.5M ($-1.11/share), driven by rising R&D spend ($108.7M vs $95.7M). The company highlighted ongoing NDA submission for darovasertib under RTOR, a new Roche collaboration for IDE892, and a strong cash position of ~$1.24B following a $323.4M June offering. The widening loss and lack of revenue growth (collaboration revenue of $8.9M is immaterial for a pre-commercial biotech) make this a neutral-to-slightly-bearish update, though the pipeline catalysts and cash runway into 2030 provide a floor.

Key Financial Metrics

EPS
−$1.22
est −$1.18 · -3.4%
Revenue
$8.9M
est $7.4M · +19.7%
Rating
in line

Key Facts

  • Net loss of $112.5M for Q2 2026, compared to $98.5M in Q1 2026.
  • R&D expenses increased to $108.7M from $95.7M sequentially.
  • Cash, cash equivalents, and marketable securities of ~$1.24B as of June 30, 2026.
  • Completed a public offering in June 2026, raising ~$323.4M in net proceeds.
  • NDA filing for darovasertib in metastatic uveal melanoma is underway under RTOR, completion expected H2 2026.
  • Announced clinical collaboration with Roche to evaluate IDE892 in combination with RG6505 in pancreatic cancer.
  • Cash runway guidance into 2030 remains unchanged.

Financial Impact

Net loss widened by $14M QoQ to $112.5M; cash position strengthened by ~$270M QoQ to $1.24B due to equity offering.

net losscash positionR&D expenses

Risk Factors

  • Darovasertib NDA may face regulatory delays or a Complete Response Letter.
  • Clinical trial failures in the ADC or MTAP pipeline could reset valuation.
  • Cash burn rate is accelerating; while runway extends to 2030, future dilution remains a risk if pipeline expands.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-331381
Document: idya-20260804.htm0001193125-26-331381
Document: 0001193125-26-331381-index-headers.html0001193125-26-331381
Document: 0001193125-26-331381-index.html0001193125-26-331381
Document: 0001193125-26-331381.txt0001193125-26-331381
8-K Data (Synthetic)0001193125-26-331381

Track record

13 reports on IDYA

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  2. Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
  3. Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
  4. Aug 4, 202614w ago 8-K Neutral 4/10 Viewing Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
  5. Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
  6. Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
  7. Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
  8. Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
  9. Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
  10. May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (10h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026